Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Non-Current Assets (2016 - 2025)

Aptevo Therapeutics' Non-Current Assets history spans 11 years, with the latest figure at $4.3 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 15.33% year-over-year to $4.3 million; the TTM value through Sep 2025 reached $18.6 million, down 14.9%, while the annual FY2024 figure was $4.9 million, 14.61% down from the prior year.
  • Non-Current Assets for Q3 2025 was $4.3 million at Aptevo Therapeutics, down from $4.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $7.4 million in Q2 2022 and bottomed at $3.5 million in Q1 2022.
  • The 5-year median for Non-Current Assets is $5.6 million (2024), against an average of $5.5 million.
  • The largest annual shift saw Non-Current Assets tumbled 43.34% in 2021 before it skyrocketed 84.62% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $4.0 million in 2021, then surged by 67.82% to $6.8 million in 2022, then decreased by 14.62% to $5.8 million in 2023, then fell by 14.61% to $4.9 million in 2024, then dropped by 11.86% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Non-Current Assets are $4.3 million (Q3 2025), $4.5 million (Q2 2025), and $4.7 million (Q1 2025).